Articles tagged "Calcineurin"

2017 American Transplant Congress
Changes in Urinary Neutrophil Gelatinase Associated Lipocalin Combined with Urine Cytokines and Microalbuminuria as Predictors for Interstitial Fibrosis and Tubular Atrophy in Kidney Transplantation: A Matched-Pair Tissue Cohort Study.
W. Chancharoenthana,¹ A. Leelahavanichkul,¹ S. Wattanatorn,¹ J. Issara-Amphorn,² Y. Avihingsanon,¹ K. Praditpornsilpa,¹ N. Townamchai.¹
¹Division of Nephrology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand; ²Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Background: Late graft loss from interstitial fibrosis - tubular atrophy (IF/TA) continues to be the “Achilles' heel” of kidney transplantation (KT). Long-term calcineurin inhibitors (CNIs)…
2017 American Transplant Congress
Felodipine Diminishes Decline in Glomerular Filtration Rate in Lung Transplanted Patients Treated with Cyclosporine: A Randomized Placebo Controlled Trial.
M. Hornum,¹ M. Iversen,² P. Oturai,³ M. Andersen,² M. Zemtsovski,⁴ P. Bredahl,⁴ N. Bjarnason,² K. Christiansen,⁵ J. Carlsen,² C. Møller,⁶ B. Feldt-Rasmussen,¹ M. Perch.²
¹Nephrology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ²Cardiology, Section for Lung Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ³Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ⁴Cardiothoracic Anaesthesiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ⁵Public Health, Section of Biostatics, University of Copenhagen, Copenhagen, Denmark; ⁶Cardiothoracic Surgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Background. Calcium channel blockers may ameliorate the decline in renal function caused by calcineurin inhibitors in lung transplant (LTX) recipients. We previously demonstrated a 47…
2017 American Transplant Congress
Variability in Tacrolimus Concentrations Across Pediatric Solid Organ Transplants.
S. Min,¹ T. Daljevic,¹ O. Lee,¹ M.-E. Alary,⁶ F. Murdoch,⁵ R. Parekh,¹ V. Ng,¹ D. Hebert,¹ L. Hamiwka,² T. Blydt-Hansen,³ V. Phan,⁴ P. Birk,³ U. Allen,¹ S. Urschel,⁵ CNTRP POSITIVE Research Group, B. Foster,⁶ S. Mital.¹
¹The Hospital for Sick Children, Toronto, Canada; ²Alberta Children's Hospital, Calgary, Canada; ³University of Winnipeg, Winnipeg, Canada; ⁴Université de Montréal, Motreal, Canada; ⁵Stollery Children's Hospital, Edmonton, Canada; ⁶McGill University, Montreal, Canada
PURPOSE: We characterized the evolution of out-of-range tacrolimus (TAC) concentrations and associated factors during 1 year following a pediatric solid organ transplant (SOT).METHODS: Heart, kidney…
2017 American Transplant Congress
Risk of Major Bleeding in Solid Organ Transplant Recipients Taking Calcineurin Inhibitors Concomitantly with Direct Oral Anticoagulants Compared to Warfarin.
J. Hazelcorn, R. Yau, N. Sabagha, M. Moaddab, M. Manson.
Pharmacy, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX
Purpose: Direct oral anticoagulants (DOAC) and calcineurin inhibitors (CNI) are both substrates of CYP 3A metabolism; therefore, the purpose of this study is to assess…
2017 American Transplant Congress
A Pilot Trial of Genotype-Guided Dosing versus Standard Clinical Dosing in Pediatric Solid Organ Transplants.
S. Min, T. Daljevic, M. Lafreniere-Roula, C. Manlhiot, N. Nalli, H. Grasemann, S. Schwartz, B. Kamath, V. Ng, R. Parekh, S. Mital.
The Hospital for Sick Children, Toronto, ON, Canada
Purpose: Tacrolimus pharmacokinetics are influenced by age and variation in the CYP3A5 gene with CYP3A5 expressors (AA/AG) being fast metabolizers. The purpose of this trial…
2017 American Transplant Congress
M1 Macrophage-Induced Loss of KLF15 Promotes Chronic Podocyte Injury.
S. Han,^1,2 Y. Kim,¹ S. Lee,¹ H. Lee,^1,2 R.-H. Cha,² J. Lee,^1,2 J. Lee,² D. Kim,^1,2 Y. Kim,^1,2 S. Yang.^1,2
¹Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; ²Kidney Research Institute, Seoul National University, Seoul, Korea
Background: Krüppel-like factor 15 (KLF15), kidney-enriched transcription factor, is known to participate in the differentiation of podocyte. However, the implication of KLF15 in chronic podocyte…
2017 American Transplant Congress
Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race.
K. Soliman, A. Posadas Salas, D. Taber.
Transplant, MUSC, Charleston, SC
There is strong evidence that both tacrolimus (FK) and mycophenolate (MMF) have improved outcomes in kidney transplantation; yet, the impact of exposure of these immunosuppressants…
2017 American Transplant Congress
Conversion from Tacrolimus-Based to Everolimus-Based Immunosuppressive Therapy 3 Months After Living-Donor Kidney Transplantation: A Randomized-Controlled Clinical Trial.
D. Hesselink,¹ N. Shuker,¹ J. Osinga,¹ M. Clahsen -van Groningen,² J. Damman,² C. Baan,¹ J. van de Wetering,¹ A. Rowshani,¹ J. Kal -van Gestel,¹ W. Weimar,¹ T. van Gelder,³ R. Bouamar.³
¹Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands; ²Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands; ³Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
While conversion from ciclosporin to everolimus is well documented, conversion from tacrolimus has been poorly studied. In this randomized-controlled trial the safety and tolerability of…
2017 American Transplant Congress
Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome.
Y. Watarai,¹ S. Narumi,¹ M. Okada,¹ R. Kimura,¹ K. Hatazoe,¹ K. Futamura,¹ T. Yamamoto,¹ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ T. Kobayashi.²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; ²Kidney Transplant Surgery, Aichi Medical University, Nagakute, Aichi, Japan
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well determined. We have validated the institutional…
2017 American Transplant Congress
Once-Daily versus Twice-Daily Tacrolimus in Living Kidney Transplantation: A Multicenter, Parallel Group, Open-Label, 5-Year, Randomized Non-Inferiority Trial.
K. Unagami,¹ M. Okumi,² T. Hirai,² D. Toki,³ H. Shirakawa,⁴ T. Shimizu,² K. Omoto,⁵ M. Inui,³ H. Ishida,² K. Nitta,¹ K. Tanabe.²
¹Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan; ³Urology, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan; ⁴Urology, Ohkubo Hospital, Tokyo, Japan; ⁵Transplant Surgery, Toda Chuo General Hospital, Toda, Japan
Background:Tacrolimus (TAC)-based induction therapy appears to be the standard immunosuppressive regimen for most kidney transplantation recipients (KTRs). TAC is available as a twice-daily (TAC-BID) and…